Loading clinical trials...
Loading clinical trials...
A Multicenter, dOuble-blind, ranDomized, Placebo-controlled, Parallel-group Study to Determine the effIcacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With FabrY Disease
Conditions
Interventions
Lucerastat
Placebo
Locations
49
United States
University of Alabama at Birmingham - Nephrology Research Clinic
Birmingham, Alabama, United States
University of California Irvine
Irvine, California, United States
UCSF Benioff Children's Hospital Oakland
Oakland, California, United States
University of Florida College of Medicine - Division of Nephrology, Hypertension & Renal Transplantation
Gainesville, Florida, United States
Emory University School of Medicine; Department of Human Genetics
Atlanta, Georgia, United States
Rush University Medical Center
Chicago, Illinois, United States
Start Date
June 21, 2018
Primary Completion Date
August 17, 2021
Completion Date
September 2, 2021
Last Updated
August 9, 2024
NCT06941025
NCT07382128
NCT05923788
NCT07277361
NCT04252066
NCT06776419
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions